Permira seeks $4 billion for sale of contract drugmaker Cambrex, FT reports

British private equity firm Permira is reportedly seeking to sell contract drugmaker Cambrex for up to $4 billion, a substantial increase from its 2019 acquisition price of approximately $2 billion. This potential divestiture follows Cambrex's significant growth, which has been fueled by global drugmakers expanding U.S. manufacturing capacity and domestic inventory. This expansion is largely a strategic response to looming drug import duties, potentially reaching 250%, proposed by President Donald Trump, underscoring the direct impact of protectionist trade policies on the pharmaceutical supply chain.

Analysis

Private equity firm Permira is seeking to capitalize on a significant shift in pharmaceutical supply chain dynamics with the potential sale of contract drugmaker Cambrex for up to $4 billion. This valuation represents a doubling of its initial $2 billion investment made in 2019, highlighting the rapid value creation within the contract development and manufacturing organization (CDMO) sector. Cambrex's growth was directly fueled by global drugmakers increasing their U.S. manufacturing capacity and domestic inventories as a strategic hedge against proposed import tariffs of up to 250%. This situation illustrates a clear causal link between protectionist trade policy and private market opportunities. The deal underscores the premium being placed on domestic manufacturing assets that can de-risk pharmaceutical supply chains. Concurrently, Permira's recent $3 billion offer for Bavarian Nordic indicates its continued bullishness and active capital deployment within the broader healthcare sector, targeting both service providers and vaccine makers.

Key Decisions for Investors

• Investors should review publicly traded pharmaceutical CDMOs with significant U.S. manufacturing footprints, as the Cambrex valuation suggests the market may be assigning a premium to assets that benefit from onshoring trends.
• Monitor trade policy and tariff-related news closely, as the Cambrex case demonstrates that geopolitical risk can be a direct and powerful catalyst for value creation in specific sectors by forcing supply chain restructuring.
• The high multiple on the potential Cambrex sale, coupled with Permira's active bidding for other assets like Bavarian Nordic, signals strong private equity appetite and may indicate that public market valuations in the healthcare and biotech sectors are attractive for take-private transactions.